Xyone Therapeutics Inc.
- | Biotech or pharma, therapeutic R&D
XYone has developed novel proprietary ADC drugs targeting an onco-protein, MUC1 to combat solid tumors. MUC1 is a pan-cancer antigen aberrantly overexpressed in over 80% of all epithelial cancer patients (~ 1.2 million patients annually in USA) and likely the most important anti-cancer target known to humanity.
Two Assets Licensed Out: XYone has successfully out-licensed two portfolio assets, validating our platform and de-risking our third platform asset.
- Roche Partnership: Our IP has been licensed to Roche/Poseida Therapeutics (PSTX) for CAR technology applications in solid tumors. This program, already in clinical trials, contributed to Poseida’s $1.5B acquisition by Roche in Nov 2024.
- NCI Endorsement : The first ADC drug has been selected for the prestigious NCI NExT program. The National Cancer Institute will fully fund and execute its development, manufacturing, and FDA approval—a $15–25M value—without taking equity or commercial rights.
Address
CantonMA
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}